You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Humanized Monoclonal Antibody to Treat Acinetobacter Infections
SBC: BIOLOGICAL ANTI-INFECTIVE MEDICINES, LLC Topic: NIAIDDESCRIPTIONprovided by applicantNational surveillance data confirm thatof Abaumannii isolates from US intensive care units are extreme drug resistanceXDRfar higher than other pathogensAt leastandcases of XDR Abaumannii infections occur annually in the US and globallyin developed countriesrespectivelyThese infections result inanddeaths and excess healthcare costs of $million and $million in the US ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Rapid Immunodiagnosis of Drug-Resistant Bacterial Pathogens
SBC: SILVER LAKE RESEARCH CORPORATION Topic: NIAIDPROJECT SUMMARY ABSTRACT This proposal describes Phase II of the development of a rapid immunoassay test kit for the determination oflactam antibiotic resistanceto be used as a point of care diagnostic test for urinary tract infectionsTodayantibiotics for UTI are prescribed empiricallywith no diagnostics available to clinicians to avoid treating resistant infections with the very drug to which the ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms
SBC: NeuroSigma, Inc. Topic: 101DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Human monoclonal antibodies for prevention of S. aureus infections
SBC: SORRENTO THERAPEUTICS, INC. Topic: NIAIDDESCRIPTION provided by applicant Using mouse monoclonal antibodies mAbs raised against the mediators of quorum sensing QS the Auto Inducing Peptides AIPs researchers at The Scripps Research Institute TSRI have demonstrated that S aureus infections can be prevented in animal challenge models This approach known as quorum quenching QQ is unique in at least two significant ways fi ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Pirenzepine for CIPN
SBC: WinSanTor, Inc. Topic: NCIPROJECT SUMMARY Chemotherapy induced peripheral neuropathyCIPNis a debilitating condition that afflictsof cancer patients undergoing chemotherapy and limits the dose and duration of treatmentSymptoms range from sensory loss to painful neuropathy and are accompanied by electrophysiological and structural indices of nerve damageThe American Society of Clinical Oncology currently makes no recommendat ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
A user-friendly scalable microfluidic platform for enhanced neuron-cell culture
SBC: Xona Microfluidics, Inc. Topic: 101DESCRIPTIONprovided by applicantNeuron cell culture is widely used for studies in basic researchdrug discoveryand toxicity testingTraditional neuron cell culture approaches result in random growth of processes which prevent the study of their unique polarized morphologyOur goal is to provide robustuser friendlyand cost effective culture platforms to manipulate and access neurons and their subcellu ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Therapeutics for inflammatory bowel disease from the microbiome
SBC: SYMBIOTIX BIOTHERAPIES, INC. Topic: 300PROJECT SUMMARY ABSTRACT Interactions between the gut microbiome and the immune system have been linked to inflammatory bowel disease IBD IBD is a chronic and progressive gastrointestinal disease characterized by uncontrolled activation of the intestinal immune system resulting in severe medical complications affecting over million patients in the United States It is a disease of high u ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
ECG Device for LQTS Screening in Newborns, Phase II
SBC: QT Medical, Inc. Topic: NHLBIDESCRIPTION provided by applicant The congenital long QT syndrome LQTS is thought to occur in in infants and cause of deaths from SIDS sudden infant death syndrome Electrocardiograms ECGs can detect LQTS before fatal cardiac events happen In our Phase I STTR project we successfully developed and tested an ECG device designed for LQTS screening in newborns This device n ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of VLP vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDDESCRIPTION provided by applicant Respiratory syncytial virus RSV is a substantial threat to human health most severely affecting three large populations infants young children and the elderly Despite the significance of RSV disease in these different populations there are no vaccines available The goal of this Phase II STTR project is to continue preclinical testing of a novel RSV vac ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health